COVID-19 大流行期间和大流行后多发性硬化症的管理更新：国际共识声明。
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
机构信息
Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Fundación Santa Fe de Bogotá, Bogotá, Colombia; School of Medicine, Universidad de los Andes, Bogotá, Colombia.
The Westmead Institute, University of Sydney, Sydney, Australia.
出版信息
J Neuroimmunol. 2021 Aug 15;357:577627. doi: 10.1016/j.jneuroim.2021.577627. Epub 2021 Jun 7.
Abstract
In this consensus statement, we provide updated recommendations on multiple sclerosis (MS) management during the COVID-19 crisis and the post-pandemic period applicable to neurology services around the world. Statements/recommendations were generated based on available literature and the experience of 13 MS expert panelists using a modified Delphi approach online. The statements/recommendations give advice regarding implementation of telemedicine; use of disease-modifying therapies and management of MS relapses; management of people with MS at highest risk from COVID-19; management of radiological monitoring; use of remote pharmacovigilance; impact on MS research; implications for lowest income settings, and other key issues.
摘要
在这份共识声明中，我们提供了在 COVID-19 危机期间和疫情后全球神经科服务中更新的多发性硬化症 (MS) 管理建议。这些声明/建议是基于现有文献和 13 名 MS 专家小组的经验，使用在线改良 Delphi 方法生成的。这些声明/建议提供了有关以下方面的建议：远程医疗的实施；疾病修正治疗的使用和 MS 复发的管理；感染 COVID-19 风险最高的 MS 患者的管理；影像学监测的管理；远程药物警戒的使用；对 MS 研究的影响；对低收入环境的影响，以及其他关键问题。
相似文献
1
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
J Neuroimmunol. 2021 Aug 15;357:577627. doi: 10.1016/j.jneuroim.2021.577627. Epub 2021 Jun 7.
2
Argentinean consensus recommendations for the use of telemedicine in clinical practice in adult people with multiple sclerosis.
Neurol Sci. 2023 Feb;44(2):667-676. doi: 10.1007/s10072-022-06471-4. Epub 2022 Nov 2.
3
Multiple sclerosis and COVID-19: The Swedish experience.
Acta Neurol Scand. 2021 Sep;144(3):229-235. doi: 10.1111/ane.13453. Epub 2021 May 24.
4
Consensus recommendations on the management of multiple sclerosis patients in Argentina.
J Neurol Sci. 2020 Feb 15;409:116609. doi: 10.1016/j.jns.2019.116609. Epub 2019 Dec 2.
5
Use of Telemedicine Among People with Multiple Sclerosis Before and During the COVID-19 Pandemic.
Telemed J E Health. 2023 Aug;29(8):1152-1163. doi: 10.1089/tmj.2022.0284. Epub 2022 Dec 9.
6
Understanding and managing the impact of the Covid-19 pandemic and lockdown on patients with multiple sclerosis.
Expert Rev Neurother. 2021 Jul;21(7):731-743. doi: 10.1080/14737175.2021.1957673. Epub 2021 Jul 24.
7
Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemic.
Mult Scler Relat Disord. 2022 Jul;63:103913. doi: 10.1016/j.msard.2022.103913. Epub 2022 May 27.
8
Assessing disability and relapses in multiple sclerosis on tele-neurology.
Neurol Sci. 2020 Jun;41(6):1369-1371. doi: 10.1007/s10072-020-04470-x. Epub 2020 May 21.
9
Era of COVID-19 in Multiple Sclerosis Care.
Neurol Clin. 2024 Feb;42(1):319-340. doi: 10.1016/j.ncl.2023.06.006. Epub 2023 Jun 23.
10
Recovery of endoscopy services in the era of COVID-19: recommendations from an international Delphi consensus.
Gut. 2020 Nov;69(11):1915-1924. doi: 10.1136/gutjnl-2020-322329. Epub 2020 Aug 14.
引用本文的文献
1
MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.
J Neurol. 2025 Mar 26;272(4):294. doi: 10.1007/s00415-025-13010-6.
2
Can tele-physiotherapy help in filling treatment gaps during pandemics in multiple sclerosis?
J Family Med Prim Care. 2024 Oct;13(10):4510-4516. doi: 10.4103/jfmpc.jfmpc_204_24. Epub 2024 Oct 18.
3
COVID-19 and multiple sclerosis: challenges and lessons for patient care.
Lancet Reg Health Eur. 2024 Aug 22;44:100979. doi: 10.1016/j.lanepe.2024.100979. eCollection 2024 Sep.
4
The impact of COVID-19 pandemic on patients with Huntington's disease and care-givers: A French survey.
eNeurologicalSci. 2024 Jul 20;36:100517. doi: 10.1016/j.ensci.2024.100517. eCollection 2024 Sep.
5
Management of patients with neurological diseases considering post-pandemic coronavirus disease 2019 (COVID-19) related risks and dangers - An updated European Academy of Neurology consensus statement.
Eur J Neurol. 2024 Oct;31(10):e16408. doi: 10.1111/ene.16408. Epub 2024 Aug 1.
6
Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina.
Clin Neuropharmacol. 2024;47(4):120-127. doi: 10.1097/WNF.0000000000000598. Epub 2024 May 22.
7
Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study.
Neurol Ther. 2024 Feb;13(1):153-164. doi: 10.1007/s40120-023-00572-8. Epub 2023 Dec 14.
8
COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece.
J Clin Med. 2023 Aug 23;12(17):5460. doi: 10.3390/jcm12175460.
9
Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study.
J Clin Med. 2023 May 24;12(11):3640. doi: 10.3390/jcm12113640.
10
Tele-Global Examination of Mental State (Tele-GEMS): an open tool for the remote neuropsychological screening.
Neurol Sci. 2023 Oct;44(10):3499-3508. doi: 10.1007/s10072-023-06862-1. Epub 2023 May 30.
本文引用的文献
1
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
Neurology. 2021 Nov 9;97(19):e1870-e1885. doi: 10.1212/WNL.0000000000012753. Epub 2021 Oct 5.
2
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835. doi: 10.1177/17562864211012835. eCollection 2021.
3
American Academy of Neurology Telehealth Position Statement.
Neurology. 2021 Aug 17;97(7):334-339. doi: 10.1212/WNL.0000000000012185. Epub 2021 May 13.
4
Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study.
CMAJ. 2021 May 17;193(20):E723-E734. doi: 10.1503/cmaj.202608. Epub 2021 Apr 27.
5
Neutralizing monoclonal antibodies for treatment of COVID-19.
Nat Rev Immunol. 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x. Epub 2021 Apr 19.
6
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
Mult Scler. 2021 May;27(6):864-870. doi: 10.1177/13524585211003476. Epub 2021 Apr 15.
7
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update.
Mult Scler Relat Disord. 2021 Jun;51:102929. doi: 10.1016/j.msard.2021.102929. Epub 2021 Mar 27.
8
Alemtuzumab in Covid era.
Mult Scler Relat Disord. 2021 Jun;51:102908. doi: 10.1016/j.msard.2021.102908. Epub 2021 Mar 18.
9
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
Mult Scler. 2022 Jan;28(1):132-138. doi: 10.1177/13524585211005339. Epub 2021 Mar 25.
10
Post-acute COVID-19 syndrome.
Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22.
Zotero 插件